Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Phosphodiesterase Type 5 (PDE5) Inhibitors.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Aug 2.

3.

Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.

Toque HA, Priviero FB, Zemse SM, Antunes E, Teixeira CE, Webb RC.

Clin Exp Pharmacol Physiol. 2009 Apr;36(4):358-66. doi: 10.1111/j.1440-1681.2008.05071.x. Epub 2008 Oct 15.

4.

Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.

Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, KaradaƟ B, Schermuly RT, Weissmann N, Seeger W, Grimminger F.

J Am Coll Cardiol. 2004 Oct 6;44(7):1488-96.

5.
6.

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.

Corbin JD, Francis SH, Webb DJ.

Urology. 2002 Sep;60(2 Suppl 2):4-11. Review.

PMID:
12414329
7.

Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.

Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MW, Bloch KD, Zapol WM.

Anesthesiology. 2000 Jun;92(6):1702-12.

PMID:
10839922
8.

Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.

Turko IV, Ballard SA, Francis SH, Corbin JD.

Mol Pharmacol. 1999 Jul;56(1):124-30.

PMID:
10385692
9.

Overview of phosphodiesterase 5 inhibition in erectile dysfunction.

Rosen RC, Kostis JB.

Am J Cardiol. 2003 Nov 6;92(9A):9M-18M. Review.

PMID:
14609619
11.

Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C.

Int J Impot Res. 1996 Jun;8(2):47-52.

PMID:
8858389
12.

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons.

Ferguson JE 3rd, Carson CC 3rd.

Arab J Urol. 2013 Sep;11(3):222-9. doi: 10.1016/j.aju.2013.07.009. Epub 2013 Sep 18. Review.

13.

Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.

Teixeira CE, Priviero FB, Webb RC.

J Pharmacol Exp Ther. 2006 Feb;316(2):654-61. Epub 2005 Oct 4.

PMID:
16204472
14.

New treatment options for erectile dysfunction in patients with diabetes mellitus.

Basu A, Ryder RE.

Drugs. 2004;64(23):2667-88. Review.

PMID:
15537369
15.

Tadalafil.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Aug 2.

16.
17.

Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction.

Goldenberg MM.

Clin Ther. 1998 Nov-Dec;20(6):1033-48. Review.

PMID:
9916601
18.

Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.

Francis SH, Morris GZ, Corbin JD.

Int J Impot Res. 2008 Jul-Aug;20(4):333-42. doi: 10.1038/ijir.2008.4. Epub 2008 Apr 17. Review.

PMID:
18418391
19.

Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.

Burnett AL.

J Androl. 2008 Jan-Feb;29(1):3-14. Epub 2007 Oct 17. Review.

20.

Supplemental Content

Support Center